Veracyte to Acquire Decipher Biosciences     Learn More
Veracyte to Acquire Decipher Biosciences     Learn More
Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 18, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson , chairman and chief executive officer, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare
Toggle Summary Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results
Fourth Quarter Revenue Increased 16% to $34.5 Million ; Volume Grew 14% to 13,130 Tests Decipher Acquisition to Expand Global Leadership in Cancer Genomic Diagnostics   While Accelerating Growth Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb.


There are currently no events to display.


Title Documents

Corporate Presentation February 2021